TGTX Capital Surpluse vs Total Liab Analysis
TGTX Stock | USD 30.69 0.96 3.03% |
TG Therapeutics financial indicator trend analysis is much more than just breaking down TG Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether TG Therapeutics is a good investment. Please check the relationship between TG Therapeutics Capital Surpluse and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.
Capital Surpluse vs Total Liab
Capital Surpluse vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of TG Therapeutics Capital Surpluse account and Total Liab. At this time, the significance of the direction appears to have very strong relationship.
The correlation between TG Therapeutics' Capital Surpluse and Total Liab is 0.86. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Total Liab in the same time period over historical financial statements of TG Therapeutics, assuming nothing else is changed. The correlation between historical values of TG Therapeutics' Capital Surpluse and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of TG Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Capital Surpluse i.e., TG Therapeutics' Capital Surpluse and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.86 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Capital Surpluse
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from TG Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into TG Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.At this time, TG Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 409.5 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 39.6 M in 2024.
TG Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
TG Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
TG Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 163.0M | 625.6M | 379.6M | 193.6M | 329.6M | 346.1M | |
Other Current Liab | 5.4M | 26.7M | 61.5M | 8.0M | 13.5M | 14.2M | |
Total Current Liabilities | 84.4M | 87.6M | 65.4M | 53.2M | 53.7M | 56.4M | |
Total Stockholder Equity | (701.2M) | 519.4M | (1.3B) | (1.5B) | 160.5M | 168.5M | |
Property Plant And Equipment Net | 11.8M | 11.8M | 11.1M | 10.8M | 8.1M | 8.6M | |
Net Debt | (71.8M) | (511.5M) | (219.8M) | (19.2M) | 17.9M | 18.8M | |
Retained Earnings | (701.2M) | (980.6M) | (1.3B) | (1.5B) | (1.5B) | (1.4B) | |
Cash | 112.6M | 553.4M | 298.9M | 102.3M | 92.9M | 59.3M | |
Non Current Assets Total | 13.9M | 13.9M | 48.7M | 25.3M | 11.6M | 7.5M | |
Cash And Short Term Investments | 140.4M | 605.4M | 350.3M | 174.1M | 217.5M | 228.4M | |
Common Stock Shares Outstanding | 88.4M | 115.3M | 132.2M | 135.4M | 148.5M | 155.9M | |
Liabilities And Stockholders Equity | (576.8M) | 625.6M | (1.2B) | (1.4B) | 329.6M | 346.1M | |
Other Stockholder Equity | (109K) | 1.5B | 1.6B | 1.6B | 1.7B | 1.8B | |
Total Liab | 124.4M | 106.3M | 142.5M | 135.0M | 169.1M | 177.5M | |
Property Plant And Equipment Gross | 11.8M | 11.8M | 11.1M | 10.8M | 9.6M | 10.0M | |
Total Current Assets | 149.2M | 611.7M | 331.0M | 168.3M | 317.9M | 333.8M | |
Non Currrent Assets Other | 1.3M | 1.3M | 1.3M | 1.3M | 1.4M | 1.3M | |
Net Receivables | 108.5K | 95K | 0.0 | 1.4M | 51.1M | 53.6M | |
Non Current Liabilities Total | 40.0M | 18.7M | 77.1M | 81.8M | 115.4M | 121.1M | |
Other Current Assets | 611K | 6.3M | 14.8M | 6.6M | 9.5M | 10.0M | |
Accounts Payable | 30.0M | 37.0M | (457K) | 42.0M | 38.5M | 40.4M | |
Common Stock Total Equity | 109K | 141K | 143K | 146K | 131.4K | 74.7K | |
Common Stock | 109K | 141K | 143K | 146K | 151K | 105.2K | |
Other Assets | 3.4M | 13.1M | 3.1M | 2.9M | 329.6M | 346.1M | |
Property Plant Equipment | 282K | 481K | 600K | 307K | 353.1K | 370.7K | |
Short Long Term Debt Total | 40.8M | 42.0M | 79.0M | 83.1M | 110.8M | 116.3M | |
Short Term Investments | 27.8M | 52.0M | 15.9M | 59.4M | 124.6M | 130.8M | |
Other Liab | 762K | 610K | 457K | 305K | 274.5K | 260.8K | |
Short Term Debt | 1.6M | 23.8M | 3.8M | 3.2M | 1.4M | 2.8M | |
Net Tangible Assets | 37.8M | 518.6M | 310.7M | 57.8M | 66.5M | 118.5M | |
Retained Earnings Total Equity | (701.2M) | (980.6M) | (1.3B) | (1.5B) | (1.4B) | (1.3B) | |
Capital Surpluse | 740.0M | 1.5B | 1.6B | 1.6B | 1.8B | 1.9B | |
Deferred Long Term Liab | 762K | 610K | 457K | 305K | 274.5K | 260.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.